FDA approves new drug for inhaled anthrax

Federal health officials say they approved a new injectable drug from Human Genome Sciences to treat inhalable anthrax.

The Food and Drug Administration says raxibacumab will provide an alternative to antibiotic drugs that are currently the standard treatment for .

Inhalation anthrax occurs when people breathe in the spores of bacteria. The infection is treated with a 60-day course of antibiotics.

Raxibacumab is a manmade protein that blocks toxins produced by anthrax. It mimics naturally occurring antibodies in the human body that find and destroy harmful substances.

The FDA approved the drug based on effectiveness studies in monkeys and rabbits that were infected with Anthrax. The drug's safety was tested in 326 healthy human volunteers.

The drug was developed by GlaxoSmithKline PLC's Human Genome Sciences.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

A faster, more sensitive method for detecting anthrax

Nov 05, 2007

Amid continuing concerns that anthrax might be used as a bioterrorism weapon, government researchers report development of a faster, more sensitive blood test for detecting the deadly toxins produced by the ...

Anthrax cellular entry point uncovered

Jan 25, 2008

The long-sought-after biological “gateway” that anthrax uses to enter healthy cells has been uncovered by microbiologists at the University of Alabama at Birmingham (UAB).

Rare anthrax case diagnosed in Minnesota

Aug 10, 2011

Minnesota health officials said Tuesday they are investigating a rare case of anthrax inhalation linked to exposure to the dreaded bacteria in the natural environment.

Recommended for you

FDA to start regulating lab-developed tests

Jul 31, 2014

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments